ARTICLE | Strategy
Solid grip on liquid cancers
December 14, 2009 8:00 AM UTC
Celgene Corp. is buying Gloucester Pharmaceuticals Inc. for Istodax romidepsin, a recently approved HDAC inhibitor that will expand its hematological malignancy franchise into T cell lymphomas.
Gloucester received FDA approval last month for Istodax as a single agent for relapsed or refractory cutaneous T cell lymphoma patients who have failed at least one systemic therapy. Market launch for the CTCL indication is planned for next year, as is an sNDA submission for peripheral T cell lymphoma (PTCL)...